Ginkgo Bioworks (DNA) Short Interest Ratio & Short Volume $11.34 +0.64 (+5.98%) (As of 01:21 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Ginkgo Bioworks Short Interest DataGinkgo Bioworks (DNA) has a short interest of 7.32 million shares, representing 19.70% of the float (the number of shares available for trading by the public). This marks a -0.14% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.5, indicating that it would take 5.5 days of the average trading volume of 1.16 million shares to cover all short positions.Current Short Interest7,320,000 sharesPrevious Short Interest7,330,000 sharesChange Vs. Previous Month-0.14%Dollar Volume Sold Short$46.63 millionShort Interest Ratio5.5 Days to CoverLast Record DateNovember 15, 2024Outstanding Shares57,479,000 sharesFloat Size37,160,000 sharesShort Percent of Float19.70%Today's Trading Volume641,334 sharesAverage Trading Volume1,158,501 sharesToday's Volume Vs. Average55% Short Selling Ginkgo Bioworks? Sign up to receive the latest short interest report for Ginkgo Bioworks and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDNA Short Interest Over TimeDNA Days to Cover Over TimeDNA Percentage of Float Shorted Over Time Ad Crypto 101 MediaCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…Click here to reserve your free seat at the Crypto Community Summit Ginkgo Bioworks Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/15/20247,320,000 shares $46.63 million -0.1%19.7%5.5 $6.37 10/31/20247,330,000 shares $55.93 million -7.0%20.7%5.4 $7.63 10/15/20247,880,000 shares $61.46 million -3.8%22.2%5.5 $7.80 9/30/20248,190,000 shares $66.87 million +29.0%23.1%5.5 $8.17 9/15/20246,350,000 shares $40.13 million -11.2%17.9%3.6 $6.32 8/31/20247,150,000 shares $47.83 million +86.2%20.2%4.5 $6.69 Get the Latest News and Ratings for DNA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter. 8/15/20243,840,000 shares $974,976.00 -96.9%10.8%2.6 $0.25 7/31/2024123,460,000 shares $46.91 million +27.0%8.7%2.1 $0.38 7/15/202497,240,000 shares $28.19 million -19.7%6.9%1.6 $0.29 6/30/2024121,100,000 shares $40.48 million -49.2%8.5%2.1 $0.33 6/15/2024238,220,000 shares $107.13 million -2.9%17.0%5.1 $0.45 5/31/2024245,410,000 shares $128.57 million -10.6%17.7%6.1 $0.52 5/15/2024274,440,000 shares $232.09 million -5.3%19.7%7.2 $0.85 4/30/2024289,730,000 shares $258.18 million +8.7%20.8%9.4 $0.89 4/15/2024266,530,000 shares $253.76 million -1.6%19.7%10.8 $0.95 3/31/2024270,830,000 shares $314.16 million +3.3%20.2%12.2 $1.16 3/15/2024262,240,000 shares $283.22 million +2.6%19.6%11.9 $1.08 2/29/2024255,720,000 shares $391.25 million +2.2%19.1%11.2 $1.53 2/15/2024250,230,000 shares $387.86 million +5.6%19.0%11.8 $1.55 1/31/2024236,910,000 shares $286.66 million +1.3%18.0%11.2 $1.21 1/15/2024233,850,000 shares $304.01 million -0.7%17.7%11.1 $1.30 12/31/2023235,500,000 shares $398.00 million -1.5%17.8%12.1 $1.69 12/15/2023239,070,000 shares $382.51 million +3.7%18.1%12.1 $1.60 11/30/2023230,480,000 shares $297.32 million +3.4%17.5%12.4 $1.29 11/15/2023222,910,000 shares $345.51 million -5.5%17.2%11.4 $1.55 10/31/2023235,940,000 shares $323.24 million +2.2%18.6%11.9 $1.37 10/15/2023230,820,000 shares $383.16 million -1.2%18.2%11.6 $1.66 9/30/2023233,540,000 shares $422.71 million -0.4%18.4%10.7 $1.81 9/15/2023234,530,000 shares $452.64 million +13.2%18.5%10.8 $1.93 8/31/2023207,170,000 shares $484.78 million +0.4%16.4%9 $2.34 8/15/2023206,330,000 shares $367.27 million -3.9%16.4%8.5 $1.78 7/31/2023214,590,000 shares $538.62 million -1.4%17.2%9.1 $2.51 7/15/2023217,710,000 shares $444.13 million -2.4%17.4%9.4 $2.04 6/30/2023223,020,000 shares $414.82 million +20.6%17.8%10.3 $1.86 6/15/2023184,920,000 shares $361.52 million +0.9%14.8%8.7 $1.96 5/31/2023183,290,000 shares $289.60 million -9.4%14.7%9.1 $1.58 5/15/2023202,240,000 shares $266.96 million +7.5%16.2%10.1 $1.32 4/30/2023188,130,000 shares $229.52 million -4.4%15.3%10 $1.22 4/15/2023196,750,000 shares $255.78 million +2.1%16.7%10.2 $1.30 3/31/2023192,710,000 shares $256.30 million +11.3%19.1%9.7 $1.33Coins Set to Soar with a Pro-Crypto White House (Ad)Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…Click here to reserve your free seat at the Crypto Community Summit 3/15/2023173,100,000 shares $230.22 million +18.4%17.1%8.3 $1.33 2/28/2023146,150,000 shares $214.84 million +16.8%14.5%6.8 $1.47 2/15/2023125,180,000 shares $227.83 million +1.4%12.4%5.9 $1.82 1/31/2023123,490,000 shares $240.81 million -1.6%12.1%5.3 $1.95 1/15/2023125,510,000 shares $233.45 million -0.6%12.4%5.3 $1.86 12/30/2022126,250,000 shares $213.36 million +10.5%12.5%5.2 $1.69 12/15/2022114,290,000 shares $186.29 million -3.6%11.0%4.5 $1.63 11/30/2022118,570,000 shares $235.95 million -4.7%12.6%4.8 $1.99 11/15/2022124,380,000 shares $332.09 million -7.3%13.2%5 $2.67 10/31/2022134,220,000 shares $366.42 million -14.1%15.7%4.9 $2.73 10/15/2022156,300,000 shares $404.82 million -8.8%19.2%5.9 $2.59 9/30/2022171,280,000 shares $534.39 million -8.7%24.2%6.8 $3.12 9/15/2022187,610,000 shares $587.22 million +4.8%22.1%7.4 $3.13 8/31/2022179,060,000 shares $481.67 million +24.1%22.8%7 $2.69 8/15/2022144,250,000 shares $503.43 million -4.0%18.4%5.5 $3.49 7/31/2022150,270,000 shares $429.77 million +3.9%19.8%6.5 $2.86 7/15/2022144,640,000 shares $433.92 million +7.5%19.1%6.2 $3.00 6/30/2022134,540,000 shares $320.21 million +22.4%17.8%5.7 $2.38 6/15/2022109,920,000 shares $284.69 million -14.7%14.6%4.3 $2.59 5/31/2022128,780,000 shares $396.64 million +19.1%17.1%5.6 $3.08 5/15/2022108,160,000 shares $287.71 million +16.9%14.4%5.2 $2.66 4/30/202292,500,000 shares $268.25 million +13.8%11.8%5 $2.90 4/15/202281,300,000 shares $312.19 million +9.7%10.3%4.6 $3.84 3/31/202274,120,000 shares $298.70 million -16.4%9.4%4.4 $4.03 3/15/202288,670,000 shares $258.03 million +2.9%9.3%7.1 $2.91 2/28/202286,190,000 shares $387.86 million +1.5%9.4%7.3 $4.50 2/15/202284,950,000 shares $471.47 million -9.2%9.2%7.5 $5.55 1/31/202293,570,000 shares $559.55 million +30.3%10.2%8.9 $5.98 1/15/202271,830,000 shares $415.90 million +30.0%8.6%8.2 $5.79 12/31/202155,270,000 shares $459.29 million No Change6.4%7 $8.31 DNA Short Interest - Frequently Asked Questions What is Ginkgo Bioworks' current short interest? Short interest is the volume of Ginkgo Bioworks shares that have been sold short but have not yet been covered or closed out. As of November 15th, traders have sold 7,320,000 shares of DNA short. 19.70% of Ginkgo Bioworks' shares are currently sold short. Learn More on Ginkgo Bioworks' current short interest. What is a good short interest ratio for Ginkgo Bioworks? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DNA shares currently have a short interest ratio of 6.0. Learn More on Ginkgo Bioworks's short interest ratio. Which institutional investors are shorting Ginkgo Bioworks? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ginkgo Bioworks: Jane Street Group LLC, Wolverine Trading LLC, Walleye Trading LLC, and Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Ginkgo Bioworks? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.70% of Ginkgo Bioworks' floating shares are currently sold short. Is Ginkgo Bioworks' short interest increasing or decreasing? Ginkgo Bioworks saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 7,320,000 shares, a decrease of 0.1% from the previous total of 7,330,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Ginkgo Bioworks' float size? Ginkgo Bioworks currently has issued a total of 57,480,000 shares. Some of Ginkgo Bioworks' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ginkgo Bioworks currently has a public float of 37,160,000 shares. How does Ginkgo Bioworks' short interest compare to its competitors? 19.70% of Ginkgo Bioworks' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Ginkgo Bioworks: Amneal Pharmaceuticals, Inc. (3.54%), Protagonist Therapeutics, Inc. (5.54%), IDEAYA Biosciences, Inc. (13.03%), Centessa Pharmaceuticals plc (2.74%), Longboard Pharmaceuticals, Inc. (5.94%), Wave Life Sciences Ltd. (4.23%), Recursion Pharmaceuticals, Inc. (21.34%), CG Oncology, Inc. (13.22%), Apogee Therapeutics, Inc. (18.26%), Akero Therapeutics, Inc. (5.19%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($4.85 billion), Charter Communications, Inc. ($4.81 billion), International Paper ($2.96 billion), Cencora, Inc. ($2.40 billion), Paychex, Inc. ($2.38 billion), Lululemon Athletica Inc. ($2.05 billion), SoFi Technologies, Inc. ($2.03 billion), Live Nation Entertainment, Inc. ($1.93 billion), Onsemi ($1.82 billion), and Tractor Supply ($1.65 billion). View all of the most shorted stocks. What does it mean to sell short Ginkgo Bioworks stock? Short selling DNA is an investing strategy that aims to generate trading profit from Ginkgo Bioworks as its price is falling. DNA shares are trading down $0.97 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ginkgo Bioworks? A short squeeze for Ginkgo Bioworks occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DNA, which in turn drives the price of the stock up even further. How often is Ginkgo Bioworks' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DNA, twice per month. The most recent reporting period available is November, 15 2024. More Short Interest Resources from MarketBeat Related Companies Amneal Pharmaceuticals Short Interest Data Protagonist Therapeutics Short Interest Data IDEAYA Biosciences Short Interest Data Centessa Pharmaceuticals Short Interest Data Longboard Pharmaceuticals Short Interest Data Wave Life Sciences Short Interest Data Recursion Pharmaceuticals Short Interest Data CG Oncology Short Interest Data Apogee Therapeutics Short Interest Data Akero Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:DNA) was last updated on 12/10/2024 by MarketBeat.com Staff From Our PartnersCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredTrump Won, But Can He Save Your 401(k)?Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your f...Priority Gold | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.